-
Loading metrics
Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT)
- Jacques De Grève,
- Jan Van Meerbeeck,
- Johan F. Vansteenkiste,
- Lore Decoster,
- Anne-Pascale Meert,
- Peter Vuylsteke,
- Christian Focan,
- Jean-Luc Canon,
- Yves Humblet,
- Guy Berchem
x
- Published: March 31, 2016
- https://doi.org/10.1371/journal.pone.0147599